IMTX Stock Forecast 2025-2026
Distance to IMTX Price Targets
IMTX Price Momentum
🤔 Considering Immatics (IMTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest IMTX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, IMTX has a bullish consensus with a median price target of $17.00 (ranging from $13.00 to $20.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.55, the median forecast implies a 273.6% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMTX Analyst Ratings
IMTX Price Target Range
Latest IMTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 19, 2024 | B of A Securities | Alex Stranahan | Buy | Maintains | $15.00 |
| Oct 7, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $19.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Sep 5, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| May 16, 2024 | Mizuho | Graig Suvannavejh | Buy | Maintains | $16.00 |
| Nov 2, 2023 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| Mar 31, 2023 | Mizuho | Graig Suvannavejh | Buy | Initiates | $12.00 |
| Mar 23, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| Aug 10, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $28.00 |
| Jun 3, 2022 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $26.00 |
| Mar 24, 2022 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $25.00 |
| Jul 15, 2021 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $27.00 |
| Mar 17, 2021 | SVB Leerink | Jonathan Chang | Outperform | Maintains | $26.00 |
| Sep 22, 2020 | Goldman Sachs | Buy | Initiates | $0.00 | |
| Jul 27, 2020 | SVB Leerink | Outperform | Initiates | $0.00 | |
| Jul 24, 2020 | Jefferies | Buy | Initiates | $0.00 |
Immatics N.V. (IMTX) Competitors
The following stocks are similar to Immatics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immatics N.V. (IMTX) Financial Data
Immatics N.V. has a market capitalization of $553.05M with a P/E ratio of 16.8x. The company generates $125.71M in trailing twelve-month revenue with a -48.3% profit margin.
Revenue growth is +753.2% quarter-over-quarter, while maintaining an operating margin of +1.0% and return on equity of -17.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Immatics N.V. (IMTX) Business Model
About Immatics N.V.
Develops T-cell redirecting cancer immunotherapies.
Immatics N.V. operates by discovering and developing innovative cancer immunotherapies that utilize the body's immune system to target and destroy cancer cells. The company generates revenue through collaborations with pharmaceutical companies, research partnerships, and potentially through the commercialization of its proprietary therapies and platforms.
Headquartered in Tuebingen, Germany, with operations in Houston, Texas, Immatics is positioned as a significant player in the biotechnology sector, particularly in oncology. Their proprietary platforms, Xpresident and ACTengine, are designed to identify tumor-specific targets, enhancing personalized treatment approaches in the rapidly evolving field of precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
572
CEO
Dr. Harpreet Singh Ph.D.
Country
Germany
IPO Year
2018
Website
www.immatics.comImmatics N.V. (IMTX) Latest News & Analysis
New Strong Buy Stocks for February 12th
1 month agoBOH, AUB, BHRB, IMTX, and RH are now rated as Zacks Rank #1 (Strong Buy) as of February 12, 2025.
Stocks BOH, AUB, BHRB, IMTX, and RH receiving a Zacks Rank #1 indicates strong growth potential and positive analyst sentiment, likely attracting investor interest and driving up share prices.
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may lead to a rise in the stock price.
Immatics' upgrade to Zacks Rank #2 signals positive earnings outlook, potentially boosting stock demand and price, attracting investor interest in the biotech sector.
New Strong Buy Stocks for January 9th
2 months agoAFRM, ZNTL, IMTX, MRCY, and DRRX have been rated as Zacks Rank #1 (Strong Buy) as of January 9, 2024.
Zacks Rank #1 indicates strong potential for these stocks, suggesting favorable outlooks and performance, attracting investor interest and potentially driving up share prices.
The Company is expanding its focus to five major cancer types using four active compounds in TCR-T cell therapies and TCR-based bispecifics.
Expanding focus on five major cancer types with active therapies may enhance the company's market potential, attract investment, and increase prospects for revenue growth and partnerships.
Immatics (IMTX) reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.27 and improving from a loss of $0.35 per share a year earlier.
Immatics' smaller-than-expected loss and improved year-over-year performance indicate better financial health, potentially boosting investor confidence and stock value.
What Makes Immatics (IMTX) a New Buy Stock
3 months agoImmatics (IMTX) has received a Zacks Rank #2 (Buy) upgrade, indicating increased optimism about its earnings prospects, which could positively impact the stock price.
Immatics' Zacks Rank upgrade to #2 signals positive earnings outlook, potentially boosting stock demand and driving prices higher in the short term.
Frequently Asked Questions About IMTX Stock
What is Immatics N.V.'s (IMTX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Immatics N.V. (IMTX) has a median price target of $17.00. The highest price target is $20.00 and the lowest is $13.00.
Is IMTX stock a good investment in 2025?
According to current analyst ratings, IMTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMTX stock?
Wall Street analysts predict IMTX stock could reach $17.00 in the next 12 months. This represents a 273.6% increase from the current price of $4.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immatics N.V.'s business model?
Immatics N.V. operates by discovering and developing innovative cancer immunotherapies that utilize the body's immune system to target and destroy cancer cells. The company generates revenue through collaborations with pharmaceutical companies, research partnerships, and potentially through the commercialization of its proprietary therapies and platforms.
What is the highest forecasted price for IMTX Immatics N.V.?
The highest price target for IMTX is $20.00 from at , which represents a 339.6% increase from the current price of $4.55.
What is the lowest forecasted price for IMTX Immatics N.V.?
The lowest price target for IMTX is $13.00 from at , which represents a 185.7% increase from the current price of $4.55.
What is the overall IMTX consensus from analysts for Immatics N.V.?
The overall analyst consensus for IMTX is bullish. Out of 7 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are IMTX stock price projections?
Stock price projections, including those for Immatics N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
